FindTrial
Sign In

Cinobufacin Combined with PD-1 inhibitor for hepatocellular carcinoma

Efficacy and Safety of Cinobufacin Combined with PD-1 inhibitor for hepatocellular carcinoma: A retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117332
Enrollment
Unknown
Registered
2026-01-22
Start date
2026-01-31
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

PD-1 inhibitor group:None
Cinobufacini combined with PD-1 inhibitor group:None

Sponsors

The Third Affiliated Hospital Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosed with HCC by imaging or pathology; 2. Age >=18 years; 3. Complete clinical and imaging follow-up records available; 4. Received treatment with HuaChanSu combined with or alone with PD-1 inhibitors.

Exclusion criteria

Exclusion criteria: 1. Other types of liver cancer or malignant tumors; 2. Previous treatment with other immune checkpoint inhibitors; 3. Incomplete clinical data or insufficient follow-up; 4. Pregnant or breastfeeding women; 5. Severe systemic diseases or history of liver transplantation.

Design outcomes

Primary

MeasureTime frame
Progression-Free Survival, PFS;Overall Survival, OS;—

Secondary

MeasureTime frame
Immune-Related Adverse Events, irAEs;Alpha-fetoprotein, AFP;—

Countries

China

Contacts

Public ContactYe Linsen

The Third Affiliated Hospital Sun Yat-sen University

ye_linsen@163.com+86 20 85252177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026